Exendin-4 inhibits structural remodeling and improves Ca2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway

Peptides

Volumn 90, Issue , 2017, Pages 69-77

  Chen, Jingjing ^a,b   Wang, Dandan ^a,b   Wang, Fangai ^a,b   Shi, Shaobo ^a,b   Chen, Yuting ^a,b   Yang, Bo ^a,b   Tang, Yanhong ^a,b   Huang, Congxin ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Exendin 4, Heart Failure, Calmodulin Dependent Kinase II, eNOS cGMP PKG Pathway, Calcium Handing

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; EXENDIN 9 39; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; CALCIUM; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CALCIUM HOMEOSTASIS; CARDIAC MUSCLE CELL; HEART; HEART FAILURE; HEART INFARCTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SARCOPLASMIC RETICULUM; AGONISTS; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CYCLIC GMP; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART FAILURE; HOMEOSTASIS; HUMANS; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDES; RATS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENOMS;

EID: 85016037090     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2017.02.008     Document Type: Article

References (49)

1. [1] Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037, 10.2337/db09-1694.
2. [2] Backs, J., Backs, T., Neef, S., Kreusser, M.M., Lehmann, L.H., Patrick, D.M., et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106 (2009), 2342–2347, 10.1073/pnas.0813013106.
3. [3] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157, 10.1053/j.gastro.2007.03.054.
4. [4] Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone, D.R., et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency. PLoS One, 6, 2011, e23570, 10.1371/journal.pone.0023570.
5. [5] Bloch, K.D., Janssens, S., Cardiomyocyte-specific overexpression of nitric oxide synthase 3: Impact on left ventricular function and myocardial infarction. Trends Cardiovasc Med 15 (2005), 249–253, 10.1016/j.tcm.2005.07.005.
6. [6] Bose, A.K., Mocanu, M.M., Carr, R.D., Brand, C.L., Yellon, D.M., Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005), 146–151, 10.2337/diabetes.54.1.146.
7. [7] Bossuyt, J., Helmstadter, K., Wu, X., Clements-Jewery, H., Haworth, R.S., Avkiran, M., et al. Ca2 + /calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 102 (2008), 695–702, 10.1161/CIRCRESAHA.107.169755.
8. [8] Bulluck, H., Yellon, D.M., Hausenloy, D.J., Reducing myocardial infarct size: Challenges and future opportunities. Heart 102 (2016), 341–348, 10.1136/heartjnl-2015-307855.
9. [9] Chen, W., Wang, R., Chen, B., Zhong, X., Kong, H., Bai, Y., et al. The ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmias. Nat Med 20 (2014), 184–192, 10.1038/nm.3440.
10. [10] Christ, M., Störk, S., Dörr, M., Heppner, H.J., Müller, C., Wachter, R., et al. Heart failure epidemiology 2000-2013: Insights from the German Federal Health Monitoring System. Eur J Heart Fail 18 (2016), 1009–1018, 10.1002/ejhf.567.
11. [11] Cook, C., Cole, G., Asaria, P., Jabbour, R., Francis, D.P., The annual global economic burden of heart failure. Int J Cardiol 171 (2014), 368–376, 10.1016/j.ijcard.2013.12.028.
12. [12] DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab 307 (2014), E630–E643, 10.1152/ajpendo.00109.2014.
13. [13] Dineen, S.L., McKenney, M.L., Bell, L.N., Fullenkamp, A.M., Schultz, K.A., Alloosh, M., et al. Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle. Diabetes 64 (2015), 3321–3327, 10.2337/db14-1790.
14. [14] Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18 (2016), 882–891, 10.1111/dom.12680.
15. [15] Edwards, J.N., Blatter, L.A., Cardiac alternans and intracellular calcium cycling. Clin Exp Pharmacol Physiol 41 (2014), 524–532, 10.1111/1440-1681.12231.
16. [16] Egholm, C., Khammy, M.M., Dalsgaard, T., Mazur, A., Tritsaris, K., Hansen, A.J., et al. GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol 311 (2016), H1214–H1224, 10.1152/ajpheart.00316.2016.
17. [17] Flaherty, M.P., Brown, M., Grupp, I.L., Schultz, J.E., Murphree, S.S., Jones, W.K., eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression. Cardiovasc Toxicol 7 (2007), 165–177, 10.1007/s12012-007-0028-y.
18. [18] Frantz, S., Klaiber, M., Baba, H.A., Oberwinkler, H., Völker, K., Gaβner, B., et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J 34 (2013), 1233–1244, 10.1093/eurheartj/ehr445.
19. [19] Hamaguchi, E., Tanaka, K., Tsutsumi, R., Sakai, Y., Fukuta, K., Kasai, A., et al. Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression. Eur Rev Med Pharmacol Sci 19 (2015), 1285–1290.
20. [20] Huang, J.H., Chen, Y.C., Lee, T.I., Kao, Y.H., Chazo, T.F., Chen, S.A., et al. Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes. Peptides 78 (2016), 91–98, 10.1016/j.peptides.2016.02.007.
21. [21] Kang, G., Chepurny, O.G., Holz, G.G., cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536 (2001), 375–385, 10.1111/j.1469-7793.2001.0375c.xd.
22. [22] Klaiber, M., Kruse, M., Völker, K., Schröter, J., Feil, R., Freichel, M., et al. Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: Role of cGMP-dependent protein kinase and RGS2. Basic Res Cardiol 105 (2010), 583–595, 10.1007/s00395-010-0098-z.
23. [23] Kreusser, M.M., Lehmann, L.H., Keranov, S., Hoting, M.O., Oehl, U., Kohlhaas, M., et al. Cardiac CaM kinase II genes delta and gamma contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation 130 (2014), 1262–1273, 10.1161/CIRCULATIONAHA.114.006185.
24. [24] Lee, J., Bae, E.H., Ma, S.K., Kim, S.W., Altered nitric oxide system in cardiovascular and renal diseases. Chonnam Med J 52 (2016), 81–90, 10.4068/cmj.2016.52.2.81.
25. [25] Lee, M.Y., Tsai, K.B., Hsu, J.H., Shin, S.J., Wu, J.R., Yeh, J.L., Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways. Sci Rep, 6, 2016, 31788, 10.1038/srep31788.
26. [26] Ling, H., Zhang, T., Pereira, L., Means, C.K., Cheng, H., Gu, Y., et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 119 (2009), 1230–1240, 10.1172/JCI38022.
27. [27] Lompré, A.M., Hajjar, R.J., Harding, S.E., Kranias, E.G., Lohse, M.J., Marks, A.R., Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 121 (2010), 822–830, 10.1161/CIRCULATIONAHA.109.890954.
28. [28] Marks, A.R., Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J Clin Invest 123 (2013), 46–52, 10.1172/JCI62834.
29. [29] Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3, 2006, e442, 10.1371/journal.pmed.0030442.
30. [30] Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58 (2009), 975–983, 10.2337/db08-1193.
31. [31] Paul, S.K., Klein, K., Maggs, D., Best, J.H., The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: A retrospective observational study. Cardiovasc Diabetol, 14, 2015, 10, 10.1186/s12933-015-0178-3.
32. [32] Pinto, J.M., Yuan, F., Wasserlauf, B.J., Bassett, A.L., Myerburg, R.J., Regional gradation of L-type calcium currents in the feline heart with a healed myocardial infarct. J Cardiovasc Electrophysiol 8 (1997), 548–560, 10.1111/j.1540-8167.1997.tb00823.x.
33. [33] Raake, P.W., Zhang, X., Vinge, L.E., Brinks, H., Gao, E., Jaleel, N., et al. Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation 125 (2012), 2108–2118, 10.1161/CIRCULATIONAHA.111.044255.
34. [34] Richards, P., Parker, H.E., Adriaenssens, A.E., Hodgson, J.M., Cork, S.C., Trapp, S., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63 (2014), 1224–1233, 10.2337/db13-1440.
35. [35] Robinson, E., Cassidy, R.S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D., et al. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol, 110, 2015, 20, 10.1007/s00395-015-0476-7.
36. [36] Shan, Y., Wang, D., Li, R., Huang, C., Molsidomine attenuates ventricular electrical remodeling and arrhythmogenesis in rats with chronic beta-adrenergic receptor activation through the NO/cGMP/PKG pathway. J Cardiovasc Pharmacol 68 (2016), 342–355, 10.1097/FJC.0000000000000422.
37. [37] Sisley, S., Smith, K., Sandoval, D.A., Seeley, R.J., Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats. Peptides 58 (2014), 1–6, 10.1016/j.peptides.2014.05.008.
38. [38] Swaminathan, P.D., Purohit, A., Hund, T.J., Anderson, M.E., Calmodulin-dependent protein kinase II: Linking heart failure and arrhythmias. Circ Res 110 (2012), 1661–1677, 10.1161/CIRCRESAHA.111.243956.
39. [39] Ussher, J.R., Baggio, L.L., Campbell, J.E., Mulvihill, E.E., Kim, M., Kabir, M.G., et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 3 (2014), 507–517, 10.1016/j.molmet.2014.04.009.
40. [40] Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojevic, S., et al. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol 89 (2015), 365–375, 10.1016/j.yjmcc.2015.09.018.
41. [41] Wang, D., Liu, T., Shi, S., Li, R., Shan, Y., Huang, Y., et al. Chronic administration of Catestatin improves autonomic function and exerts cardioprotective effects in myocardial infarction rats. J Cardiovasc Pharmacol Ther 21 (2016), 526–535, 10.1177/1074248416628676.
42. [42] Wehrens, X.H., Lehnart, S.E., Reiken, S.R., Marks, A.R., Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94 (2004), e61–e70, 10.1161/01.RES.0000125626.33738.E2.
43. [43] Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab 310 (2016), E947–E957, 10.1152/ajpendo.00400.2015.
44. [44] Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002), 43–52, 10.1172/JCI15595.
45. [45] Younce, C.W., Burmeister, M.A., Ayala, J.E., Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 304 (2013), C508–C518, 10.1152/ajpcell.00248.2012.
46. [46] Younce, C.W., Niu, J., Ayala, J., Burmeister, M.A., Smith, L.H., Kolattukudy, P., et al. Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes. J Mol Cell Cardiol 76 (2014), 172–176, 10.1016/j.yjmcc.2014.08.022.
47. [47] Zhang, T., Kohlhaas, M., Backs, J., Mishra, S., Phillips, W., Dybkova, N., et al. CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 282 (2007), 35078–35087, 10.1074/jbc.M707083200.
48. [48] Zhang, T., Maier, L.S., Dalton, N.D., Miyamoto, S., Ross, J.J., Bers, D.M., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92 (2003), 912–919, 10.1161/01.RES.0000069686.31472.C5.
49. [49] Zhou, Y., He, X., Chen, Y., Huang, Y., Wu, L., He, J., Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation. Biochem Biophys Res Commun 468 (2015), 394–399, 10.1016/j.bbrc.2015.09.179.